Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Expert Stresses Promotion of Technology Transfer: JPMA Symposium
January 14, 2002
- Sequelae of Cerebral Hemorrhage Deleted from Ketas Indications
January 14, 2002
- To Play a Meaningful Social Role, Become Independent, and Increase Profitability
January 14, 2002
- Long-listed Drugs Account for up to 60% of Total Sales: Top 10 Companies
January 14, 2002
- BUSINESS NEWS IN BRIEF
January 14, 2002
- Price Cutting Rates for Long-listed Drugs Likely to Be 3-tiered
January 14, 2002
- Vital-Net to Acquire Shares of Inoue Seishodo
January 14, 2002
- Home Caregivers of Dementia Patients under Severe Stress: Eisai, Pfizer Seminar
January 14, 2002
- Korosho Budget Totals \18,668.4 Bil., Up 3.2%
January 14, 2002
- Fukujin Takes Over Ethical Drugs, Lab Reagents from Inagaki
January 14, 2002
- Business Improves for Local Government-managed Hospitals
January 14, 2002
- 6 Products Including Flutide 200 Diskus Added to NHI List
January 14, 2002
- 9 Wholesalers Accept FTC Recommendation: Cartel Affair in Tohoku
January 14, 2002
- LDP to Review Operations of Univ., Social Insurance Hospitals
January 14, 2002
- OPSR, PMDEC to Be Merged: Administrative Reform
January 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 14, 2002
- IFN to Be Re-priced Next April
January 14, 2002
- Suntory, Sankyo Codevelop Glucagon-like Peptide-1 as Antidiabetic
January 14, 2002
- Ceiling of Copayment for the Elderly Decided
January 14, 2002
- Standard Format for Package Inserts for Medical Devices Issued
January 14, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…